IntrinsicIntrinsic
OverviewFinancialsChartBusiness SummaryFilingsOwnershipValuation

iBio, Inc. (IBIO)

Business Summary

iBio, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence for the development of hard-to-drug precision antibodies for obesity, cardiometabolic and cardiopulmonary diseases. The company's core mission is to harness AI and machine learning to unveil novel biologics, with a focus on next-generation antibody therapeutics that address limitations of current GLP-1 receptor agonist treatments, such as muscle loss, fat regain after treatment cessation, and long-term tolerability. The company is prioritizing targets with strong human genetic and clinical validation and is evaluating adjacent indications including pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF).

The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition, and a strong emphasis on proprietary products. iBio faces competition from fully integrated pharmaceutical companies such as Eli Lilly and Company, Novo Nordisk A/S, Amgen Inc., Bristol-Myers Squibb Company, Merck & Co., Inc., Novartis AG, MedImmune, LLC, Johnson & Johnson, Pfizer Inc., Merck KGaA, and Sanofi SA, as well as more established biotechnology companies such as Genentech, Inc. and Regeneron Pharmaceuticals, Inc. The company also competes with companies more advanced in the obesity and cardiometabolic space, including Keros Therapeutics, Inc., Scholar Rock Holding Corporation, Biohaven, Ltd., Structure Therapeutics, Inc., Viking Therapeutics, Inc., and others, as well as tech-enabled drug discovery companies such as Recursion Pharmaceuticals, Inc. and AbCellera Biologics, Inc. Many competitors have significantly greater financial resources and expertise, and the company believes its potential advantages lie in its new technologies, including its AI Drug Discovery Platform.

iBio's business model is centered on developing next-generation antibody medicines for obesity and its cardiometabolic and cardiopulmonary complications. The company generates revenue through strategic collaborations, out-licensing its AI Drug Discovery Platform to partners in diverse therapeutic areas such as immunology, inflammation, pain, and vaccines, and potentially through milestone payments and sublicense fees from its exclusive license agreements. The company's strategy includes developing and advancing its pipeline cost-effectively, pursuing strategic collaborations using its existing portfolio of obesity and immuno-oncology assets, and out-licensing its platform to generate non-dilutive cash flow while maintaining operational focus on internal R&D priorities.

IBIO-600 is a long-acting myostatin antibody, currently in a Phase 1 clinical trial in Australia, with 31 participants enrolled across four single ascending dose cohorts. Preclinical studies in obese non-human primates demonstrated a half-life of approximately 52.4 days, with estimated human half-life ranging from 57-147 days, and lean mass gains of up to 5.1%. IBIO-610 is a potentially first-in-class, long-acting antibody designed to inhibit Activin E, with preclinical data showing an 8.9% reduction in body weight in diet-induced obesity mice, a 26% reduction in fat mass, and a 35.3% weight loss when combined with semaglutide. In obese non-human primates, IBIO-610 demonstrated a terminal half-life of approximately 33.2 days, a projected human half-life of up to 100 days, and reduced active Activin E levels by 98% at week 4 and 97% at week 8.

IBIO-800 is a myostatin × Activin A bispecific antibody being evaluated for potential use in PH-HFpEF, with a development candidate nominated in June 2026 and IND-enabling activities initiated. The company is also developing an amylin receptor agonist engineered antibody program in collaboration with AstralBio, which has generated dual amylin and calcitonin receptor agonist (DACRA) antibodies and selective amylin receptor agonist (SARA) antibodies. In a proof-of-concept study in DIO mice, an early DACRA-like agonist antibody delivered approximately a 60% reduction in acute food intake, compared with a 67% reduction observed with a benchmark DACRA peptide. The company's AI Drug Discovery Platform includes Epitope Steering, StableHu, and EngageTx technologies, with the platform capable of progressing from concept to development-ready antibody in as little as seven months.

In fiscal year 2026, iBio achieved several key milestones, including dosing the first participant in the Phase 1 clinical trial of IBIO-600 in June 2026, approximately two years after program initiation. The company closed a public offering in August 2025 for total gross proceeds of up to $100 million, led by Balyasny Asset Management, and a private investment in January 2026 for total gross proceeds of $26 million, led by Frazier Life Sciences. The company also entered into an Open Market Sale Agreement with Jefferies LLC for the sale of up to $100,000,000 of shares of Common Stock. In August 2026, the company entered into an exclusive license agreement with AstralBio for Amylin, with an upfront license fee of $750,000 and milestone payments of up to an aggregate of $28 million. The company also appointed Dr. Elizabeth Stoner to the Board and Dr. Molly Carr as Chief Medical Officer.

iBio reported a net loss of approximately $33.0 million for the fiscal year ended June 30, 2026, compared to a net loss of approximately $18.4 million for the fiscal year ended June 30, 2025. As of June 30, 2026, the company had an accumulated deficit of approximately $365.3 million. Research and development expenses were $19.6 million in fiscal year 2026, compared to $8.3 million in fiscal year 2025. The company received approximately $46.5 million in net proceeds from the August 2025 underwritten offering and expects to continue incurring significant operating losses as it advances its clinical and preclinical programs.

Business Outlook & Financial Sufficiency

iBio anticipates commencing first-in-human clinical trials for IBIO-610 in the first half of calendar year 2027. The company is preparing to advance IBIO-600 into the multiple ascending dose (MAD) portion of its Phase 1 study, with study completion expected in the second half of 2027. The company expects its research and development expenses to increase significantly as its product candidates advance in clinical development and as it adds more employees, and it anticipates incurring significant and increasing operating losses and negative cash flows for the foreseeable future.

The company is advancing IBIO-610, a long-acting Activin E antibody, into IND-enabling studies, including CMC development and GLP toxicology studies in rats and non-human primates. Preclinical data demonstrated a prolonged half-life and near-complete suppression of active Activin E through eight weeks in obese non-human primates, as well as fat-specific activity and enhanced body-composition effects in combination with semaglutide. The company believes these findings support IBIO-610's potential for best-in-class pathway inhibition and support the potential for an infrequently dosed, long-acting antibody approach, with a projected human half-life of up to 100 days.

The company is advancing IBIO-800, a myostatin × Activin A bispecific antibody, into IND-enabling development, having selected a development candidate in June 2026 and initiated CMC development and nonclinical toxicology studies. Preclinical data supports its potential to preserve muscle and address cardiopulmonary disease, particularly PH-HFpEF. The company is also expanding its amylin receptor antibody program in collaboration with AstralBio, combining engineered GPCR antigens with mammalian display-based combinatorial selection to generate next-generation agonist antibodies with distinct and differentiated amylin receptor pharmacology, including DACRA and SARA antibodies.

iBio's margin and cost outlook is characterized by expectations of significantly increasing research and development expenses as product candidates advance in clinical development. The company expects to continue to incur significant and increasing operating losses and negative cash flows for the foreseeable future, with expenses increasing due to the ongoing Phase 1 clinical trial of IBIO-600, continued IND-enabling studies for IBIO-610, and additional studies required to support development of other preclinical cardiometabolic and cardiopulmonary programs. The company also anticipates incurring significant costs associated with commercial launch and commercial-scale manufacturing requirements if any product candidates are approved.

iBio's operational outlook includes reliance on third-party manufacturers for all clinical manufacturing, as the company does not own or operate facilities for clinical drug manufacturing, storage, distribution, or quality testing. The company has entered into agreements with five contract research organizations for CMC development, non-clinical toxicology, and related studies to advance IBIO-600 and IBIO-610 towards clinical testing. The company has 23 employees as of August 27, 2026, all full-time, in addition to two strategic consultants, and anticipates needing to attract new talent to achieve its plans for growth. The company has made substantial investments in digital infrastructure, including robotics, automation, AI, ML, and cloud computing.

iBio's capital allocation strategy includes significant investment in research and development, with R&D expenses of $19.6 million in fiscal year 2026. The company closed a public offering in August 2025 for total gross proceeds of up to $100 million, a private investment in January 2026 for total gross proceeds of $26 million, and entered into an Open Market Sale Agreement with Jefferies LLC for the sale of up to $100,000,000 of shares of Common Stock. The company does not anticipate paying cash dividends for the foreseeable future. The company also has milestone payment obligations of up to $28 million under each of its license agreements with AstralBio, which can be paid in cash or shares of Common Stock.

iBio faces significant headwinds and constraints, including a limited operating history, a history of significant losses, and the need for additional funding to fully execute its business plan. The company received approximately $46.5 million in net proceeds from the August 2025 offering but will need additional capital as it does not anticipate any product candidates generating revenue in the next few years. The company's pipeline is concentrated in a single therapeutic area, increasing its exposure to setbacks in that area. The company also faces risks related to conducting clinical trials in Australia, reliance on third-party manufacturers and suppliers, and the potential for delays in patient enrollment.

The company's business is subject to risks related to the development and commercialization of its technologies and product candidates, including the risk that preclinical and clinical development involves a lengthy and expensive process with an uncertain outcome. The company has not yet demonstrated its ability to successfully complete any clinical trials, obtain regulatory approvals, manufacture a commercial scale product, or conduct sales and marketing activities necessary for successful product commercialization. The company also faces risks related to its dependence on licensed intellectual property, third-party CROs, and the potential for manufacturing problems experienced by third parties.

Management Sentiments & Priorities

Management's message emphasizes the company's transition to a clinical-stage biotechnology company with the dosing of the first participant in the Phase 1 clinical trial of IBIO-600 in June 2026, marking the first molecule generated using its AI Drug Discovery Platform to advance into clinical development. The company highlights its progress on obesity and cardiometabolic pipeline, including advancing IBIO-610 into IND-enabling studies, advancing IBIO-800 into IND-enabling development, and expanding the amylin receptor antibody program with AstralBio. Management emphasizes financial stability through the closing of a public offering in August 2025 for total gross proceeds of up to $100 million and a private investment in January 2026 for total gross proceeds of $26 million, as well as strengthening the Board and senior leadership team. The strategic priorities for the period ahead include developing next-generation antibody therapeutics addressing limitations of currently approved treatments, prioritizing targets with strong human genetic and clinical validation, and applying the integrated AI Drug Discovery Platform to rapidly generate and advance development-ready biologics.

Financial Details

For the fiscal year ended June 30, 2026, iBio reported a net loss of approximately $33.0 million, compared to a net loss of approximately $18.4 million for the fiscal year ended June 30, 2025. Research and development expenses were $19.6 million in fiscal year 2026, compared to $8.3 million in fiscal year 2025. As of June 30, 2026, the company had an accumulated deficit of approximately $365.3 million. The company received approximately $46.5 million in net proceeds from the August 2025 underwritten offering. The company's cash position is expected to limit the number of product candidates it seeks to develop, and it will need additional capital to fully implement its long-term business, operating, and development plans. The company does not anticipate generating significant revenue for several years and may never achieve or maintain profitability.

Risk Factors

iBio faces significant risks including a limited operating history with no approved products or significant revenue, and a history of significant losses with a net loss of approximately $33.0 million for fiscal year 2026 and an accumulated deficit of approximately $365.3 million as of June 30, 2026. The company will need additional funding, having received approximately $46.5 million in net proceeds from the August 2025 offering, but does not anticipate any product candidates generating revenue in the next few years. The pipeline is concentrated in a single therapeutic area, increasing exposure to setbacks, and the company has fully impaired its IBIO-101 asset and ceased active marketing of its oncology programs. The company relies on a limited number of product candidates, with only IBIO-600 in a Phase 1 clinical trial and all others in preclinical development, and faces risks related to the lengthy and expensive clinical trial process, potential delays in patient enrollment, and the uncertainty of regulatory approval. The company also depends on licensed intellectual property from AstralBio, with milestone payments of up to $28 million per license agreement, and relies on third-party manufacturers and CROs for clinical manufacturing and development activities.

References

  1. [1] Item 1, Business — Overview
  2. [2] Item 1, Business — Competition
  3. [3] Item 1, Business — Strategy
  4. [4] Item 1, Business — IBIO-600
  5. [5] Item 1, Business — IBIO-610
  6. [6] Item 1, Business — IBIO-610
  7. [7] Item 1, Business — IBIO-610
  8. [8] Item 1, Business — IBIO-610
  9. [9] Item 1, Business — IBIO-610
  10. [10] Item 1, Business — IBIO-610
  11. [11] Item 1, Business — IBIO-610
  12. [12] Item 1, Business — IBIO-610
  13. [13] Item 1, Business — IBIO-610
  14. [14] Item 1, Business — IBIO-610
  15. [15] Item 1, Business — IBIO-610
  16. [16] Item 1, Business — IBIO-610
  17. [17] Item 1, Business — IBIO-610
  18. [18] Item 1, Business — IBIO-610
  19. [19] Item 1, Business — IBIO-610
  20. [20] Item 1, Business — IBIO-610
  21. [21] Item 1, Business — IBIO-610
  22. [22] Item 1, Business — IBIO-610
  23. [23] Item 1, Business — IBIO-610
  24. [24] Item 1, Business — IBIO-610
  25. [25] Item 1, Business — IBIO-610
  26. [26] Item 1, Business — IBIO-610
  27. [27] Item 1, Business — IBIO-610
  28. [28] Item 1, Business — IBIO-610
  29. [29] Item 1, Business — IBIO-610
  30. [30] Item 1, Business — IBIO-610
  31. [31] Item 1, Business — IBIO-610
  32. [32] Item 1, Business — IBIO-610
  33. [33] Item 1, Business — IBIO-610
  34. [34] Item 1, Business — IBIO-610
  35. [35] Item 1, Business — IBIO-610
  36. [36] Item 1, Business — IBIO-610
  37. [37] Item 1, Business — IBIO-610
  38. [38] Item 1, Business — IBIO-610
  39. [39] Item 1, Business — IBIO-610
  40. [40] Item 1, Business — IBIO-610
  41. [41] Item 1, Business — IBIO-610
  42. [42] Item 1, Business — IBIO-610
  43. [43] Item 1, Business — IBIO-610
  44. [44] Item 1, Business — IBIO-610
  45. [45] Item 1, Business — IBIO-610
  46. [46] Item 1, Business — IBIO-610
  47. [47] Item 1, Business — IBIO-610
  48. [48] Item 1, Business — IBIO-610
  49. [49] Item 1, Business — IBIO-610
  50. [50] Item 1, Business — IBIO-610
  51. [51] Item 1, Business — IBIO-610
  52. [52] Item 1, Business — IBIO-610
  53. [53] Item 1, Business — IBIO-610
  54. [54] Item 1, Business — IBIO-610
  55. [55] Item 1, Business — IBIO-610
  56. [56] Item 1, Business — IBIO-610
  57. [57] Item 1, Business — IBIO-610
  58. [58] Item 1, Business — IBIO-610
  59. [59] Item 1, Business — IBIO-610
  60. [60] Item 1, Business — IBIO-610
  61. [61] Item 1, Business — IBIO-610
  62. [62] Item 1, Business — IBIO-610
  63. [63] Item 1, Business — IBIO-610
  64. [64] Item 1, Business — IBIO-610
  65. [65] Item 1, Business — IBIO-610
  66. [66] Item 1, Business — IBIO-610
  67. [67] Item 1, Business — IBIO-610
  68. [68] Item 1, Business — IBIO-610
  69. [69] Item 1, Business — IBIO-610
  70. [70] Item 1, Business — IBIO-610
  71. [71] Item 1, Business — IBIO-610
  72. [72] Item 1, Business — IBIO-610
  73. [73] Item 1, Business — IBIO-610
  74. [74] Item 1, Business — IBIO-610
  75. [75] Item 1, Business — IBIO-610
  76. [76] Item 1, Business — IBIO-610
  77. [77] Item 1, Business — IBIO-610
  78. [78] Item 1, Business — IBIO-610
  79. [79] Item 1, Business — IBIO-610
  80. [80] Item 1, Business — IBIO-610
  81. [81] Item 1, Business — IBIO-610
  82. [82] Item 1, Business — IBIO-610
  83. [83] Item 1, Business — IBIO-610
  84. [84] Item 1, Business — IBIO-610
  85. [85] Item 1, Business — IBIO-610
  86. [86] Item 1, Business — IBIO-610
  87. [87] Item 1, Business — IBIO-610
  88. [88] Item 1, Business — IBIO-610
  89. [89] Item 1, Business — IBIO-610
  90. [90] Item 1, Business — IBIO-610
  91. [91] Item 1, Business — IBIO-610
  92. [92] Item 1, Business — IBIO-610
  93. [93] Item 1, Business — IBIO-610
  94. [94] Item 1, Business — IBIO-610
  95. [95] Item 1, Business — IBIO-610
  96. [96] Item 1, Business — IBIO-610
  97. [97] Item 1, Business — IBIO-610
  98. [98] Item 1, Business — IBIO-610
  99. [99] Item 1, Business — IBIO-610
  100. [100] Item 1, Business — IBIO-610
  101. [101] Item 1, Business — IBIO-610
  102. [102] Item 1, Business — IBIO-610
  103. [103] Item 1, Business — IBIO-610
  104. [104] Item 1, Business — IBIO-610
  105. [105] Item 1, Business — IBIO-610
  106. [106] Item 1, Business — IBIO-610
  107. [107] Item 1, Business — IBIO-610
  108. [108] Item 1, Business — IBIO-610
  109. [109] Item 1, Business — IBIO-610
  110. [110] Item 1, Business — IBIO-610
  111. [111] Item 1, Business — IBIO-610
  112. [112] Item 1, Business — IBIO-610
  113. [113] Item 1, Business — IBIO-610
  114. [114] Item 1, Business — IBIO-610
  115. [115] Item 1, Business — IBIO-610
  116. [116] Item 1, Business — IBIO-610
  117. [117] Item 1, Business — IBIO-610
  118. [118] Item 1, Business — IBIO-610
  119. [119] Item 1, Business — IBIO-610
  120. [120] Item 1, Business — IBIO-610
  121. [121] Item 1, Business — IBIO-610
  122. [122] Item 1, Business — IBIO-610
  123. [123] Item 1, Business — IBIO-610
  124. [124] Item 1, Business — IBIO-610
  125. [125] Item 1, Business — IBIO-610
  126. [126] Item 1, Business — IBIO-610
  127. [127] Item 1, Business — IBIO-610
  128. [128] Item 1, Business — IBIO-610
  129. [129] Item 1, Business — IBIO-610
  130. [130] Item 1, Business — IBIO-610
  131. [131] Item 1, Business — IBIO-610
  132. [132] Item 1, Business — IBIO-610
  133. [133] Item 1, Business — IBIO-610
  134. [134] Item 1, Business — IBIO-610
  135. [135] Item 1, Business — IBIO-610
  136. [136] Item 1, Business — IBIO-610
  137. [137] Item 1, Business — IBIO-610
  138. [138] Item 1, Business — IBIO-610
  139. [139] Item 1, Business — IBIO-610
  140. [140] Item 1, Business — IBIO-610
  141. [141] Item 1, Business — IBIO-610
  142. [142] Item 1, Business — IBIO-610
  143. [143] Item 1, Business — IBIO-610
  144. [144] Item 1, Business — IBIO-610
  145. [145] Item 1, Business — IBIO-610
  146. [146] Item 1, Business — IBIO-610
  147. [147] Item 1, Business — IBIO-610
  148. [148] Item 1, Business — IBIO-610
  149. [149] Item 1, Business — IBIO-610
  150. [150] Item 1, Business — IBIO-610
  151. [151] Item 1, Business — IBIO-610
  152. [152] Item 1, Business — IBIO-610
  153. [153] Item 1, Business — IBIO-610
  154. [154] Item 1, Business — IBIO-610
  155. [155] Item 1, Business — IBIO-610
  156. [156] Item 1, Business — IBIO-610
  157. [157] Item 1, Business — IBIO-610
  158. [158] Item 1, Business — IBIO-610
  159. [159] Item 1, Business — IBIO-610
  160. [160] Item 1, Business — IBIO-610
  161. [161] Item 1, Business — IBIO-610
  162. [162] Item 1, Business — IBIO-610
  163. [163] Item 1, Business — IBIO-610
  164. [164] Item 1, Business — IBIO-610
  165. [165] Item 1, Business — IBIO-610
  166. [166] Item 1, Business — IBIO-610
  167. [167] Item 1, Business — IBIO-610
  168. [168] Item 1, Business — IBIO-610
  169. [169] Item 1, Business — IBIO-610
  170. [170] Item 1, Business — IBIO-610
  171. [171] Item 1, Business — IBIO-610
  172. [172] Item 1, Business — IBIO-610
  173. [173] Item 1, Business — IBIO-610
  174. [174] Item 1, Business — IBIO-610
  175. [175] Item 1, Business — IBIO-610
  176. [176] Item 1, Business — IBIO-610
  177. [177] Item 1, Business — IBIO-610
  178. [178] Item 1, Business — IBIO-610
  179. [179] Item 1, Business — IBIO-610
  180. [180] Item 1, Business — IBIO-610
  181. [181] Item 1, Business — IBIO-610
  182. [182] Item 1, Business — IBIO-610
  183. [183] Item 1, Business — IBIO-610
  184. [184] Item 1, Business — IBIO-610
  185. [185] Item 1, Business — IBIO-610
  186. [186] Item 1, Business — IBIO-610
  187. [187] Item 1, Business — IBIO-610
  188. [188] Item 1, Business — IBIO-610
  189. [189] Item 1, Business — IBIO-610
  190. [190] Item 1, Business — IBIO-610
  191. [191] Item 1, Business — IBIO-610
  192. [192] Item 1, Business — IBIO-610
  193. [193] Item 1, Business — IBIO-610
  194. [194] Item 1, Business — IBIO-610
  195. [195] Item 1, Business — IBIO-610
  196. [196] Item 1, Business — IBIO-610
  197. [197] Item 1, Business — IBIO-610
  198. [198] Item 1, Business — IBIO-610
  199. [199] Item 1, Business — IBIO-610
  200. [200] Item 1, Business — IBIO-610
  201. [201] Item 1, Business — IBIO-610
  202. [202] Item 1, Business — IBIO-610
  203. [203] Item 1, Business — IBIO-610
  204. [204] Item 1, Business — IBIO-610
  205. [205] Item 1, Business — IBIO-610
  206. [206] Item 1, Business — IBIO-610
  207. [207] Item 1, Business — IBIO-610
  208. [208] Item 1, Business — IBIO-610
  209. [209] Item 1, Business — IBIO-610
  210. [210] Item 1, Business — IBIO-610
  211. [211] Item 1, Business — IBIO-610
  212. [212] Item 1, Business — IBIO-610
  213. [213] Item 1, Business — IBIO-610
  214. [214] Item 1, Business — IBIO-610
  215. [215] Item 1, Business — IBIO-610
  216. [216] Item 1, Business — IBIO-610
  217. [217] Item 1, Business — IBIO-610
  218. [218] Item 1, Business — IBIO-610
  219. [219] Item 1, Business — IBIO-610
  220. [220] Item 1, Business — IBIO-610
  221. [221] Item 1, Business — IBIO-610
  222. [222] Item 1, Business — IBIO-610
  223. [223] Item 1, Business — IBIO-610
  224. [224] Item 1, Business — IBIO-610
  225. [225] Item 1, Business — IBIO-610
  226. [226] Item 1, Business — IBIO-610
  227. [227] Item 1, Business — IBIO-610
  228. [228] Item 1, Business — IBIO-610
  229. [229] Item 1, Business — IBIO-610
  230. [230] Item 1, Business — IBIO-610
  231. [231] Item 1, Business — IBIO-610
  232. [232] Item 1, Business — IBIO-610
  233. [233] Item 1, Business — IBIO-610
  234. [234] Item 1, Business — IBIO-610
  235. [235] Item 1, Business — IBIO-610
  236. [236] Item 1, Business — IBIO-610
  237. [237] Item 1, Business — IBIO-610
  238. [238] Item 1, Business — IBIO-610
  239. [239] Item 1, Business — IBIO-610
  240. [240] Item 1, Business — IBIO-610
  241. [241] Item 1, Business — IBIO-610
  242. [242] Item 1, Business — IBIO-610
  243. [243] Item 1, Business — IBIO-610
  244. [244] Item 1, Business — IBIO-610
  245. [245] Item 1, Business — IBIO-610
  246. [246] Item 1, Business — IBIO-610
  247. [247] Item 1, Business — IBIO-610
  248. [248] Item 1, Business — IBIO-610
  249. [249] Item 1, Business — IBIO-610
  250. [250] Item 1, Business — IBIO-610
  251. [251] Item 1, Business — IBIO-610
  252. [252] Item 1, Business — IBIO-610
  253. [253] Item 1, Business — IBIO-610
  254. [254] Item 1, Business — IBIO-610
  255. [255] Item 1, Business — IBIO-610
  256. [256] Item 1, Business — IBIO-610
  257. [257] Item 1, Business — IBIO-610
  258. [258] Item 1, Business — IBIO-610
  259. [259] Item 1, Business — IBIO-610
  260. [260] Item 1, Business — IBIO-610
  261. [261] Item 1, Business — IBIO-610
  262. [262] Item 1, Business — IBIO-610
  263. [263] Item 1, Business — IBIO-610
  264. [264] Item 1, Business — IBIO-610
  265. [265] Item 1, Business — IBIO-610
  266. [266] Item 1, Business — IBIO-610
  267. [267] Item 1, Business — IBIO-610
  268. [268] Item 1, Business — IBIO-610
  269. [269] Item 1, Business — IBIO-610
  270. [270] Item 1, Business — IBIO-610
  271. [271] Item 1, Business — IBIO-610
  272. [272] Item 1, Business — IBIO-610
  273. [273] Item 1, Business — IBIO-610
  274. [274] Item 1, Business — IBIO-610
  275. [275] Item 1, Business — IBIO-610
  276. [276] Item 1, Business — IBIO-610
  277. [277] Item 1, Business — IBIO-610
  278. [278] Item 1, Business — IBIO-610
  279. [279] Item 1, Business — IBIO-610
  280. [280] Item 1, Business — IBIO-610
  281. [281] Item 1, Business — IBIO-610
  282. [282] Item 1, Business — IBIO-610
  283. [283] Item 1, Business — IBIO-610
  284. [284] Item 1, Business — IBIO-610
  285. [285] Item 1, Business — IBIO-610
  286. [286] Item 1, Business — IBIO-610
  287. [287] Item 1, Business — IBIO-610
  288. [288] Item 1, Business — IBIO-610
  289. [289] Item 1, Business — IBIO-610
  290. [290] Item 1, Business — IBIO-610
  291. [291] Item 1, Business — IBIO-610
  292. [292] Item 1, Business — IBIO-610
  293. [293] Item 1, Business — IBIO-610
  294. [294] Item 1, Business — IBIO-610
  295. [295] Item 1, Business — IBIO-610
  296. [296] Item 1, Business — IBIO-610
  297. [297] Item 1, Business — IBIO-610
  298. [298] Item 1, Business — IBIO-610
  299. [299] Item 1, Business — IBIO-610
  300. [300] Item 1, Business — IBIO-610
  301. [301] Item 1, Business — IBIO-610
  302. [302] Item 1, Business — IBIO-610
  303. [303] Item 1, Business — IBIO-610
  304. [304] Item 1, Business — IBIO-610
  305. [305] Item 1, Business — IBIO-610
  306. [306] Item 1, Business — IBIO-610
  307. [307] Item 1, Business — IBIO-610
  308. [308] Item 1, Business — IBIO-610
  309. [309] Item 1, Business — IBIO-610
  310. [310] Item 1, Business — IBIO-610
  311. [311] Item 1, Business — IBIO-610
  312. [312] Item 1, Business — IBIO-610
  313. [313] Item 1, Business — IBIO-610
  314. [314] Item 1, Business — IBIO-610
  315. [315] Item 1, Business — IBIO-610
  316. [316] Item 1, Business — IBIO-610
  317. [317] Item 1, Business — IBIO-610
  318. [318] Item 1, Business — IBIO-610
  319. [319] Item 1, Business — IBIO-610
  320. [320] Item 1, Business — IBIO-610
  321. [321] Item 1, Business — IBIO-610
  322. [322] Item 1, Business — IBIO-610
  323. [323] Item 1, Business — IBIO-610
  324. [324] Item 1, Business — IBIO-610
  325. [325] Item 1, Business — IBIO-610
  326. [326] Item 1, Business — IBIO-610
  327. [327] Item 1, Business — IBIO-610
  328. [328] Item 1, Business — IBIO-610
  329. [329] Item 1, Business — IBIO-610
  330. [330] Item 1, Business — IBIO-610
  331. [331] Item 1, Business — IBIO-610
  332. [332] Item 1, Business — IBIO-610
  333. [333] Item 1, Business — IBIO-610
  334. [334] Item 1, Business — IBIO-610
  335. [335] Item 1, Business — IBIO-610
  336. [336] Item 1, Business — IBIO-610
  337. [337] Item 1, Business — IBIO-610
  338. [338] Item 1, Business — IBIO-610
  339. [339] Item 1, Business — IBIO-610
  340. [340] Item 1, Business — IBIO-610
  341. [341] Item 1, Business — IBIO-610
  342. [342] Item 1, Business — IBIO-610
  343. [343] Item 1, Business — IBIO-610
  344. [344] Item 1, Business — IBIO-610
  345. [345] Item 1, Business — IBIO-610
  346. [346] Item 1, Business — IBIO-610
  347. [347] Item 1, Business — IBIO-610
  348. [348] Item 1, Business — IBIO-610
  349. [349] Item 1, Business — IBIO-610
  350. [350] Item 1, Business — IBIO-610
  351. [351] Item 1, Business — IBIO-610
  352. [352] Item 1, Business — IBIO-610
  353. [353] Item 1, Business — IBIO-610
  354. [354] Item 1, Business — IBIO-610
  355. [355] Item 1, Business — IBIO-610
  356. [356] Item 1, Business — IBIO-610
  357. [357] Item 1, Business — IBIO-610
  358. [358] Item 1, Business — IBIO-610
  359. [359] Item 1, Business — IBIO-610
  360. [360] Item 1, Business — IBIO-610
  361. [361] Item 1, Business — IBIO-610
  362. [362] Item 1, Business — IBIO-610
  363. [363] Item 1, Business — IBIO-610
  364. [364] Item 1, Business — IBIO-610
  365. [365] Item 1, Business — IBIO-610
  366. [366] Item 1, Business — IBIO-610
  367. [367] Item 1, Business — IBIO-610
  368. [368] Item 1, Business — IBIO-610
  369. [369] Item 1, Business — IBIO-610
  370. [370] Item 1, Business — IBIO-610
  371. [371] Item 1, Business — IBIO-610
  372. [372] Item 1, Business — IBIO-610
  373. [373] Item 1, Business — IBIO-610
  374. [374] Item 1, Business — IBIO-610
  375. [375] Item 1, Business — IBIO-610
  376. [376] Item 1, Business — IBIO-610
  377. [377] Item 1, Business — IBIO-610
  378. [378] Item 1, Business — IBIO-610
  379. [379] Item 1, Business — IBIO-610
  380. [380] Item 1, Business — IBIO-610
  381. [381] Item 1, Business — IBIO-610
  382. [382] Item 1, Business — IBIO-610
  383. [383] Item 1, Business — IBIO-610
  384. [384] Item 1, Business — IBIO-610
  385. [385] Item 1, Business — IBIO-610
  386. [386] Item 1, Business — IBIO-610
  387. [387] Item 1, Business — IBIO-610
  388. [388] Item 1, Business — IBIO-610
  389. [389] Item 1, Business — IBIO-610
  390. [390] Item 1, Business — IBIO-610
  391. [391] Item 1, Business — IBIO-610
  392. [392] Item 1, Business — IBIO-610
  393. [393] Item 1, Business — IBIO-610
  394. [394] Item 1, Business — IBIO-610
  395. [395] Item 1, Business — IBIO-610
  396. [396] Item 1, Business — IBIO-610
  397. [397] Item 1, Business — IBIO-610
  398. [398] Item 1, Business — IBIO-610
  399. [399] Item 1, Business — IBIO-610
  400. [400] Item 1, Business — IBIO-610
  401. [401] Item 1, Business — IBIO-610
  402. [402] Item 1, Business — IBIO-610
  403. [403] Item 1, Business — IBIO-610
  404. [404] Item 1, Business — IBIO-610
  405. [405] Item 1, Business — IBIO-610
  406. [406] Item 1, Business — IBIO-610
  407. [407] Item 1, Business — IBIO-610
  408. [408] Item 1, Business — IBIO-610
  409. [409] Item 1, Business — IBIO-610
  410. [410] Item 1, Business — IBIO-610
  411. [411] Item 1, Business — IBIO-610
  412. [412] Item 1, Business — IBIO-610
  413. [413] Item 1, Business — IBIO-610
  414. [414] Item 1, Business — IBIO-610
  415. [415] Item 1, Business — IBIO-610
  416. [416] Item 1, Business — IBIO-610
  417. [417] Item 1, Business — IBIO-610
  418. [418] Item 1, Business — IBIO-610
  419. [419] Item 1, Business — IBIO-610
  420. [420] Item 1, Business — IBIO-610
  421. [421] Item 1, Business — IBIO-610
  422. [422] Item 1, Business — IBIO-610
  423. [423] Item 1, Business — IBIO-610
  424. [424] Item 1, Business — IBIO-610
  425. [425] Item 1, Business — IBIO-610
  426. [426] Item 1, Business — IBIO-610
  427. [427] Item 1, Business — IBIO-610
  428. [428] Item 1, Business — IBIO-610
  429. [429] Item 1, Business — IBIO-610
  430. [430] Item 1, Business — IBIO-610
  431. [431] Item 1, Business — IBIO-610
  432. [432] Item 1, Business — IBIO-610
  433. [433] Item 1, Business — IBIO-610
  434. [434] Item 1, Business — IBIO-610
  435. [435] Item 1, Business — IBIO-610
  436. [436] Item 1, Business — IBIO-610
  437. [437] Item 1, Business — IBIO-610
  438. [438] Item 1, Business — IBIO-610
  439. [439] Item 1, Business — IBIO-610
  440. [440] Item 1, Business — IBIO-610
  441. [441] Item 1, Business — IBIO-610
  442. [442] Item 1, Business — IBIO-610
  443. [443] Item 1, Business — IBIO-610
  444. [444] Item 1, Business — IBIO-610
  445. [445] Item 1, Business — IBIO-610
  446. [446] Item 1, Business — IBIO-610
  447. [447] Item 1, Business — IBIO-610
  448. [448] Item 1, Business — IBIO-610
  449. [449] Item 1, Business — IBIO-610
  450. [450] Item 1, Business — IBIO-610
  451. [451] Item 1, Business — IBIO-610
  452. [452] Item 1, Business — IBIO-610
  453. [453] Item 1, Business — IBIO-610
  454. [454] Item 1, Business — IBIO-610
  455. [455] Item 1, Business — IBIO-610
  456. [456] Item 1, Business — IBIO-610
  457. [457] Item 1, Business — IBIO-610
  458. [458] Item 1, Business — IBIO-610
  459. [459] Item 1, Business — IBIO-610
  460. [460] Item 1, Business — IBIO-610
  461. [461] Item 1, Business — IBIO-610
  462. [462] Item 1, Business — IBIO-610
  463. [463] Item 1, Business — IBIO-610
  464. [464] Item 1, Business — IBIO-610
  465. [465] Item 1, Business — IBIO-610
  466. [466] Item 1, Business — IBIO-610
  467. [467] Item 1, Business — IBIO-610
  468. [468] Item 1, Business — IBIO-610
  469. [469] Item 1, Business — IBIO-610
  470. [470] Item 1, Business — IBIO-610
  471. [471] Item 1, Business — IBIO-610
  472. [472] Item 1, Business — IBIO-610
  473. [473] Item 1, Business — IBIO-610
  474. [474] Item 1, Business — IBIO-610
  475. [475] Item 1, Business — IBIO-610
  476. [476] Item 1, Business — IBIO-610
  477. [477] Item 1, Business — IBIO-610
  478. [478] Item 1, Business — IBIO-610
  479. [479] Item 1, Business — IBIO-610
  480. [480] Item 1, Business — IBIO-610
  481. [481] Item 1, Business — IBIO-610
  482. [482] Item 1, Business — IBIO-610
  483. [483] Item 1, Business — IBIO-610
  484. [484] Item 1, Business — IBIO-610
  485. [485] Item 1, Business — IBIO-610
  486. [486] Item 1, Business — IBIO-610
  487. [487] Item 1, Business — IBIO-610
  488. [488] Item 1, Business — IBIO-610
  489. [489] Item 1, Business — IBIO-610
  490. [490] Item 1, Business — IBIO-610
  491. [491] Item 1, Business — IBIO-610
  492. [492] Item 1, Business — IBIO-610
  493. [493] Item 1, Business — IBIO-610
  494. [494] Item 1, Business — IBIO-610
  495. [495] Item 1, Business — IBIO-610
  496. [496] Item 1, Business — IBIO-610
  497. [497] Item 1, Business — IBIO-610
  498. [498] Item 1, Business — IBIO-610
  499. [499] Item 1, Business — IBIO-610
  500. [500] Item 1, Business — IBIO-610
  501. [501] Item 1, Business — IBIO-610
  502. [502] Item 1, Business — IBIO-610
  503. [503] Item 1, Business — IBIO-610
  504. [504] Item 1, Business — IBIO-610
  505. [505] Item 1, Business — IBIO-610
  506. [506] Item 1, Business — IBIO-610
  507. [507] Item 1, Business — IBIO-610
  508. [508] Item 1, Business — IBIO-610
  509. [509] Item 1, Business — IBIO-610
  510. [510] Item 1, Business — IBIO-610
  511. [511] Item 1, Business — IBIO-610
  512. [512] Item 1, Business — IBIO-610
  513. [513] Item 1, Business — IBIO-610
  514. [514] Item 1, Business — IBIO-610
  515. [515] Item 1, Business — IBIO-610
  516. [516] Item 1, Business — IBIO-610
  517. [517] Item 1, Business — IBIO-610
  518. [518] Item 1, Business — IBIO-610
  519. [519] Item 1, Business — IBIO-610
  520. [520] Item 1, Business — IBIO-610
  521. [521] Item 1, Business — IBIO-610
  522. [522] Item 1, Business — IBIO-610
  523. [523] Item 1, Business — IBIO-610
  524. [524] Item 1, Business — IBIO-610
  525. [525] Item 1, Business — IBIO-610
  526. [526] Item 1, Business — IBIO-610
  527. [527] Item 1, Business — IBIO-610
  528. [528] Item 1, Business — IBIO-610
  529. [529] Item 1, Business — IBIO-610
  530. [530] Item 1, Business — IBIO-610
  531. [531] Item 1, Business — IBIO-610
  532. [532] Item 1, Business — IBIO-610
  533. [533] Item 1, Business — IBIO-610
  534. [534] Item 1, Business — IBIO-610
  535. [535] Item 1, Business — IBIO-610
  536. [536] Item 1, Business — IBIO-610
  537. [537] Item 1, Business — IBIO-610
  538. [538] Item 1, Business — IBIO-610
  539. [539] Item 1, Business — IBIO-610
  540. [540] Item 1, Business — IBIO-610
  541. [541] Item 1, Business — IBIO-610
  542. [542] Item 1, Business — IBIO-610
  543. [543] Item 1, Business — IBIO-610
  544. [544] Item 1, Business — IBIO-610
  545. [545] Item 1, Business — IBIO-610
  546. [546] Item 1, Business — IBIO-610
  547. [547] Item 1, Business — IBIO-610
  548. [548] Item 1, Business — IBIO-610
  549. [549] Item 1, Business — IBIO-610
  550. [550] Item 1, Business — IBIO-610
  551. [551] Item 1, Business — IBIO-610
  552. [552] Item 1, Business — IBIO-610
  553. [553] Item 1, Business — IBIO-610
  554. [554] Item 1, Business — IBIO-610
  555. [555] Item 1, Business — IBIO-610
  556. [556] Item 1, Business — IBIO-610
  557. [557] Item 1, Business — IBIO-610
  558. [558] Item 1, Business — IBIO-610
  559. [559] Item 1, Business — IBIO-610
  560. [560] Item 1, Business — IBIO-610
  561. [561] Item 1, Business — IBIO-610
  562. [562] Item 1, Business — IBIO-610
  563. [563] Item 1, Business — IBIO-610
  564. [564] Item 1, Business — IBIO-610
  565. [565] Item 1, Business — IBIO-610
  566. [566] Item 1, Business — IBIO-610
  567. [567] Item 1, Business — IBIO-610
  568. [568] Item 1, Business — IBIO-610
  569. [569] Item 1, Business — IBIO-610
  570. [570] Item 1, Business — IBIO-610
  571. [571] Item 1, Business — IBIO-610
  572. [572] Item 1, Business — IBIO-610
  573. [573] Item 1, Business — IBIO-610
  574. [574] Item 1, Business — IBIO-610
  575. [575] Item 1, Business — IBIO-610
  576. [576] Item 1, Business — IBIO-610
  577. [577] Item 1, Business — IBIO-610
  578. [578] Item 1, Business — IBIO-610
  579. [579] Item 1, Business — IBIO-610
  580. [580] Item 1, Business — IBIO-610
  581. [581] Item 1, Business — IBIO-610
  582. [582] Item 1, Business — IBIO-610
  583. [583] Item 1, Business — IBIO-610
  584. [584] Item 1, Business — IBIO-610
  585. [585] Item 1, Business — IBIO-610
  586. [586] Item 1, Business — IBIO-610
  587. [587] Item 1, Business — IBIO-610
  588. [588] Item 1, Business — IBIO-610
  589. [589] Item 1, Business — IBIO-610
  590. [590] Item 1, Business — IBIO-610
  591. [591] Item 1, Business — IBIO-610
  592. [592] Item 1, Business — IBIO-610
  593. [593] Item 1, Business — IBIO-610
  594. [594] Item 1, Business — IBIO-610
  595. [595] Item 1, Business — IBIO-610
  596. [596] Item 1, Business — IBIO-610
  597. [597] Item 1, Business — IBIO-610
  598. [598] Item 1, Business — IBIO-610
  599. [599] Item 1, Business — IBIO-610
  600. [600] Item 1, Business — IBIO-610
  601. [601] Item 1, Business — IBIO-610
  602. [602] Item 1, Business — IBIO-610
  603. [603] Item 1, Business — IBIO-610
  604. [604] Item 1, Business — IBIO-610
  605. [605] Item 1, Business — IBIO-610
  606. [606] Item 1, Business — IBIO-610
  607. [607] Item 1, Business — IBIO-610
  608. [608] Item 1, Business — IBIO-610
  609. [609] Item 1, Business — IBIO-610
  610. [610] Item 1, Business — IBIO-610
  611. [611] Item 1, Business — IBIO-610
  612. [612] Item 1, Business — IBIO-610
  613. [613] Item 1, Business — IBIO-610
  614. [614] Item 1, Business — IBIO-610
  615. [615] Item 1, Business — IBIO-610
  616. [616] Item 1, Business — IBIO-610
  617. [617] Item 1, Business — IBIO-610
  618. [618] Item 1, Business — IBIO-610
  619. [619] Item 1, Business — IBIO-610
  620. [620] Item 1, Business — IBIO-610
  621. [621] Item 1, Business — IBIO-610
  622. [622] Item 1, Business — IBIO-610
  623. [623] Item 1, Business — IBIO-610
  624. [624] Item 1, Business — IBIO-610
  625. [625] Item 1, Business — IBIO-610
  626. [626] Item 1, Business — IBIO-610
  627. [627] Item 1, Business — IBIO-610
  628. [628] Item 1, Business — IBIO-610
  629. [629] Item 1, Business — IBIO-610
  630. [630] Item 1, Business — IBIO-610
  631. [631] Item 1, Business — IBIO-610
  632. [632] Item 1, Business — IBIO-610
  633. [633] Item 1, Business — IBIO-610
  634. [634] Item 1, Business — IBIO-610
  635. [635] Item 1, Business — IBIO-610
  636. [636] Item 1, Business — IBIO-610
  637. [637] Item 1, Business — IBIO-610
  638. [638] Item 1, Business — IBIO-610
  639. [639] Item 1, Business — IBIO-610
  640. [640] Item 1, Business — IBIO-610
  641. [641] Item 1, Business — IBIO-610
  642. [642] Item 1, Business — IBIO-610
  643. [643] Item 1, Business — IBIO-610
  644. [644] Item 1, Business — IBIO-610
  645. [645] Item 1, Business — IBIO-610
  646. [646] Item 1, Business — IBIO-610
  647. [647] Item 1, Business — IBIO-610
  648. [648] Item 1, Business — IBIO-610
  649. [649] Item 1, Business — IBIO-610
  650. [650] Item 1, Business — IBIO-610
  651. [651] Item 1, Business — IBIO-610
  652. [652] Item 1, Business — IBIO-610
  653. [653] Item 1, Business — IBIO-610
  654. [654] Item 1, Business — IBIO-610
  655. [655] Item 1, Business — IBIO-610
  656. [656] Item 1, Business — IBIO-610
  657. [657] Item 1, Business — IBIO-610
  658. [658] Item 1, Business — IBIO-610
  659. [659] Item 1, Business — IBIO-610
  660. [660] Item 1, Business — IBIO-610
  661. [661] Item 1, Business — IBIO-610
  662. [662] Item 1, Business — IBIO-610
  663. [663] Item 1, Business — IBIO-610
  664. [664] Item 1, Business — IBIO-610
  665. [665] Item 1, Business — IBIO-610
  666. [666] Item 1, Business — IBIO-610
  667. [667] Item 1, Business — IBIO-610
  668. [668] Item 1, Business — IBIO-610
  669. [669] Item 1, Business — IBIO-610
  670. [670] Item 1, Business — IBIO-610
  671. [671] Item 1, Business — IBIO-610
  672. [672] Item 1, Business — IBIO-610
  673. [673] Item 1, Business — IBIO-610
  674. [674] Item 1, Business — IBIO-610
  675. [675] Item 1, Business — IBIO-610
  676. [676] Item 1, Business — IBIO-610
  677. [677] Item 1, Business — IBIO-610
  678. [678] Item 1, Business — IBIO-610
  679. [679] Item 1, Business — IBIO-610
  680. [680] Item 1, Business — IBIO-610
  681. [681] Item 1, Business — IBIO-610
  682. [682] Item 1, Business — IBIO-610
  683. [683] Item 1, Business — IBIO-610
  684. [684] Item 1, Business — IBIO-610
  685. [685] Item 1, Business — IBIO-610
  686. [686] Item 1, Business — IBIO-610
  687. [687] Item 1, Business — IBIO-610
  688. [688] Item 1, Business — IBIO-610
  689. [689] Item 1, Business — IBIO-610
  690. [690] Item 1, Business — IBIO-610
  691. [691] Item 1, Business — IBIO-610
  692. [692] Item 1, Business — IBIO-610
  693. [693] Item 1, Business — IBIO-610
  694. [694] Item 1, Business — IBIO-610
  695. [695] Item 1, Business — IBIO-610
  696. [696] Item 1, Business — IBIO-610
  697. [697] Item 1, Business — IBIO-610
  698. [698] Item 1, Business — IBIO-610
  699. [699] Item 1, Business — IBIO-610
  700. [700] Item 1, Business — IBIO-610
  701. [701] Item 1, Business — IBIO-610
  702. [702] Item 1, Business — IBIO-610
  703. [703] Item 1, Business — IBIO-610
  704. [704] Item 1, Business — IBIO-610
  705. [705] Item 1, Business — IBIO-610
  706. [706] Item 1, Business — IBIO-610
  707. [707] Item 1, Business — IBIO-610
  708. [708] Item 1, Business — IBIO-610
  709. [709] Item 1, Business — IBIO-610
  710. [710] Item 1, Business — IBIO-610
  711. [711] Item 1, Business — IBIO-610
  712. [712] Item 1, Business — IBIO-610
  713. [713] Item 1, Business — IBIO-610
  714. [714] Item 1, Business — IBIO-610
  715. [715] Item 1, Business — IBIO-610
  716. [716] Item 1, Business — IBIO-610
  717. [717] Item 1, Business — IBIO-610
  718. [718] Item 1, Business — IBIO-610
  719. [719] Item 1, Business — IBIO-610
  720. [720] Item 1, Business — IBIO-610
  721. [721] Item 1, Business — IBIO-610
  722. [722] Item 1, Business — IBIO-610
  723. [723] Item 1, Business — IBIO-610
  724. [724] Item 1, Business — IBIO-610
  725. [725] Item 1, Business — IBIO-610
  726. [726] Item 1, Business — IBIO-610
  727. [727] Item 1, Business — IBIO-610
  728. [728] Item 1, Business — IBIO-610
  729. [729] Item 1, Business — IBIO-610
  730. [730] Item 1, Business — IBIO-610
  731. [731] Item 1, Business — IBIO-610
  732. [732] Item 1, Business — IBIO-610
  733. [733] Item 1, Business — IBIO-610
  734. [734] Item 1, Business — IBIO-610
  735. [735] Item 1, Business — IBIO-610
  736. [736] Item 1, Business — IBIO-610
  737. [737] Item 1, Business — IBIO-610
  738. [738] Item 1, Business — IBIO-610
  739. [739] Item 1, Business — IBIO-610
  740. [740] Item 1, Business — IBIO-610
  741. [741] Item 1, Business — IBIO-610
  742. [742] Item 1, Business — IBIO-610
  743. [743] Item 1, Business — IBIO-610
  744. [744] Item 1, Business — IBIO-610
  745. [745] Item 1, Business — IBIO-610
  746. [746] Item 1, Business — IBIO-610
  747. [747] Item 1, Business — IBIO-610
  748. [748] Item 1, Business — IBIO-610
  749. [749] Item 1, Business — IBIO-610
  750. [750] Item 1, Business — IBIO-610
  751. [751] Item 1, Business — IBIO-610
  752. [752] Item 1, Business — IBIO-610
  753. [753] Item 1, Business — IBIO-610
  754. [754] Item 1, Business — IBIO-610
  755. [755] Item 1, Business — IBIO-610
  756. [756] Item 1, Business — IBIO-610
  757. [757] Item 1, Business — IBIO-610
  758. [758] Item 1, Business — IBIO-610
  759. [759] Item 1, Business — IBIO-610
  760. [760] Item 1, Business — IBIO-610
  761. [761] Item 1, Business — IBIO-610
  762. [762] Item 1, Business — IBIO-610
  763. [763] Item 1, Business — IBIO-610
  764. [764] Item 1, Business — IBIO-610
  765. [765] Item 1, Business — IBIO-610
  766. [766] Item 1, Business — IBIO-610
  767. [767] Item 1, Business — IBIO-610
  768. [768] Item 1, Business — IBIO-610
  769. [769] Item 1, Business — IBIO-610
  770. [770] Item 1, Business — IBIO-610
  771. [771] Item 1, Business — IBIO-610
  772. [772] Item 1, Business — IBIO-610
  773. [773] Item 1, Business — IBIO-610
  774. [774] Item 1, Business — IBIO-610
  775. [775] Item 1, Business — IBIO-610
  776. [776] Item 1, Business — IBIO-610
  777. [777] Item 1, Business — IBIO-610
  778. [778] Item 1, Business — IBIO-610
  779. [779] Item 1, Business — IBIO-610
  780. [780] Item 1, Business — IBIO-610
  781. [781] Item 1, Business — IBIO-610
  782. [782] Item 1, Business — IBIO-610
  783. [783] Item 1, Business — IBIO-610
  784. [784] Item 1, Business — IBIO-610
  785. [785] Item 1, Business — IBIO-610
  786. [786] Item 1, Business — IBIO-610
  787. [787] Item 1, Business — IBIO-610
  788. [788] Item 1, Business — IBIO-610
  789. [789] Item 1, Business — IBIO-610
  790. [790] Item 1, Business — IBIO-610
  791. [791] Item 1, Business — IBIO-610
  792. [792] Item 1, Business — IBIO-610
  793. [793] Item 1, Business — IBIO-610
  794. [794] Item 1, Business — IBIO-610
  795. [795] Item 1, Business — IBIO-610
  796. [796] Item 1, Business — IBIO-610
  797. [797] Item 1, Business — IBIO-610
  798. [798] Item 1, Business — IBIO-610
  799. [799] Item 1, Business — IBIO-610
  800. [800] Item 1, Business — IBIO-610
  801. [801] Item 1, Business — IBIO-610
  802. [802] Item 1, Business — IBIO-610
  803. [803] Item 1, Business — IBIO-610
  804. [804] Item 1, Business — IBIO-610
  805. [805] Item 1, Business — IBIO-610
  806. [806] Item 1, Business — IBIO-610
  807. [807] Item 1, Business — IBIO-610
  808. [808] Item 1, Business — IBIO-610
  809. [809] Item 1, Business — IBIO-610
  810. [810] Item 1, Business — IBIO-610
  811. [811] Item 1, Business — IBIO-610
  812. [812] Item 1, Business — IBIO-610
  813. [813] Item 1, Business — IBIO-610
  814. [814] Item 1, Business — IBIO-610
  815. [815] Item 1, Business — IBIO-610
  816. [816] Item 1, Business — IBIO-610
  817. [817] Item 1, Business — IBIO-610
  818. [818] Item 1, Business — IBIO-610
  819. [819] Item 1, Business — IBIO-610
  820. [820] Item 1, Business — IBIO-610
  821. [821] Item 1, Business — IBIO-610
  822. [822] Item 1, Business — IBIO-610
  823. [823] Item 1, Business — IBIO-610
  824. [824] Item 1, Business — IBIO-610
  825. [825] Item 1, Business — IBIO-610
  826. [826] Item 1, Business — IBIO-610
  827. [827] Item 1, Business — IBIO-610
  828. [828] Item 1, Business — IBIO-610
  829. [829] Item 1, Business — IBIO-610
  830. [830] Item 1, Business — IBIO-610
  831. [831] Item 1, Business — IBIO-610
  832. [832] Item 1, Business — IBIO-610
  833. [833] Item 1, Business — IBIO-610
  834. [834] Item 1, Business — IBIO-610
  835. [835] Item 1, Business — IBIO-610
  836. [836] Item 1, Business — IBIO-610
  837. [837] Item 1, Business — IBIO-610
  838. [838] Item 1, Business — IBIO-610
  839. [839] Item 1, Business — IBIO-610
  840. [840] Item 1, Business — IBIO-610
  841. [841] Item 1, Business — IBIO-610
  842. [842] Item 1, Business — IBIO-610
  843. [843] Item 1, Business — IBIO-610
  844. [844] Item 1, Business — IBIO-610
  845. [845] Item 1, Business — IBIO-610
  846. [846] Item 1, Business — IBIO-610
  847. [847] Item 1, Business — IBIO-610
  848. [848] Item 1, Business — IBIO-610
  849. [849] Item 1, Business — IBIO-610
  850. [850] Item 1, Business — IBIO-610
  851. [851] Item 1, Business — IBIO-610
  852. [852] Item 1, Business — IBIO-610
  853. [853] Item 1, Business — IBIO-610
  854. [854] Item 1, Business — IBIO-610
  855. [855] Item 1, Business — IBIO-610
  856. [856] Item 1, Business — IBIO-610
  857. [857] Item 1, Business — IBIO-610
  858. [858] Item 1, Business — IBIO-610
  859. [859] Item 1, Business — IBIO-610
  860. [860] Item 1, Business — IBIO-610
  861. [861] Item 1, Business — IBIO-610
  862. [862] Item 1, Business — IBIO-610
  863. [863] Item 1, Business — IBIO-610
  864. [864] Item 1, Business — IBIO-610
  865. [865] Item 1, Business — IBIO-610
  866. [866] Item 1, Business — IBIO-610
  867. [867] Item 1, Business — IBIO-610
  868. [868] Item 1, Business — IBIO-610
  869. [869] Item 1, Business — IBIO-610
  870. [870] Item 1, Business — IBIO-610
  871. [871] Item 1, Business — IBIO-610
  872. [872] Item 1, Business — IBIO-610
  873. [873] Item 1, Business — IBIO-610
  874. [874] Item 1, Business — IBIO-610
  875. [875] Item 1, Business — IBIO-610
  876. [876] Item 1, Business — IBIO-610
  877. [877] Item 1, Business — IBIO-610
  878. [878] Item 1, Business — IBIO-610
  879. [879] Item 1, Business — IBIO-610
  880. [880] Item 1, Business — IBIO-610
  881. [881] Item 1, Business — IBIO-610
  882. [882] Item 1, Business — IBIO-610
  883. [883] Item 1, Business — IBIO-610
  884. [884] Item 1, Business — IBIO-610
  885. [885] Item 1, Business — IBIO-610
  886. [886] Item 1, Business — IBIO-610
  887. [887] Item 1, Business — IBIO-610
  888. [888] Item 1, Business — IBIO-610
  889. [889] Item 1, Business — IBIO-610
  890. [890] Item 1, Business — IBIO-610
  891. [891] Item 1, Business — IBIO-610
  892. [892] Item 1, Business — IBIO-610
  893. [893] Item 1, Business — IBIO-610
  894. [894] Item 1, Business — IBIO-610
  895. [895] Item 1, Business — IBIO-610
  896. [896] Item 1, Business — IBIO-610
  897. [897] Item 1, Business — IBIO-610
  898. [898] Item 1, Business — IBIO-610
  899. [899] Item 1, Business — IBIO-610
  900. [900] Item 1, Business — IBIO-610
  901. [901] Item 1, Business — IBIO-610
  902. [902] Item 1, Business — IBIO-610
  903. [903] Item 1, Business — IBIO-610
  904. [904] Item 1, Business — IBIO-610
  905. [905] Item 1, Business — IBIO-610
  906. [906] Item 1, Business — IBIO-610
  907. [907] Item 1, Business — IBIO-610
  908. [908] Item 1, Business — IBIO-610
  909. [909] Item 1, Business — IBIO-610
  910. [910] Item 1, Business — IBIO-610
  911. [911] Item 1, Business — IBIO-610
  912. [912] Item 1, Business — IBIO-610
  913. [913] Item 1, Business — IBIO-610
  914. [914] Item 1, Business — IBIO-610
  915. [915] Item 1, Business — IBIO-610
  916. [916] Item 1, Business — IBIO-610
  917. [917] Item 1, Business — IBIO-610
  918. [918] Item 1, Business — IBIO-610
  919. [919] Item 1, Business — IBIO-610
  920. [920] Item 1, Business — IBIO-610
  921. [921] Item 1, Business — IBIO-610
  922. [922] Item 1, Business — IBIO-610
  923. [923] Item 1, Business — IBIO-610
  924. [924] Item 1, Business — IBIO-610
  925. [925] Item 1, Business — IBIO-610
  926. [926] Item 1, Business — IBIO-610
  927. [927] Item 1, Business — IBIO-610
  928. [928] Item 1, Business — IBIO-610
  929. [929] Item 1, Business — IBIO-610
  930. [930] Item 1, Business — IBIO-610
  931. [931] Item 1, Business — IBIO-610
  932. [932] Item 1, Business — IBIO-610
  933. [933] Item 1, Business — IBIO-610
  934. [934] Item 1, Business — IBIO-610
  935. [935] Item 1, Business — IBIO-610
  936. [936] Item 1, Business — IBIO-610
  937. [937] Item 1, Business — IBIO-610
  938. [938] Item 1, Business — IBIO-610
  939. [939] Item 1, Business — IBIO-610
  940. [940] Item 1, Business — IBIO-610
  941. [941] Item 1, Business — IBIO-610
  942. [942] Item 1, Business — IBIO-610
  943. [943] Item 1, Business — IBIO-610
  944. [944] Item 1, Business — IBIO-610
  945. [945] Item 1, Business — IBIO-610
  946. [946] Item 1, Business — IBIO-610
  947. [947] Item 1, Business — IBIO-610
  948. [948] Item 1, Business — IBIO-610
  949. [949] Item 1, Business — IBIO-610
  950. [950] Item 1, Business — IBIO-610
  951. [951] Item 1, Business — IBIO-610
  952. [952] Item 1, Business — IBIO-610
  953. [953] Item 1, Business — IBIO-610
  954. [954] Item 1, Business — IBIO-610
  955. [955] Item 1, Business — IBIO-610
  956. [956] Item 1, Business — IBIO-610
  957. [957] Item 1, Business — IBIO-610
  958. [958] Item 1, Business — IBIO-610
  959. [959] Item 1, Business — IBIO-610
  960. [960] Item 1, Business — IBIO-610
  961. [961] Item 1, Business — IBIO-610
  962. [962] Item 1, Business — IBIO-610
  963. [963] Item 1, Business — IBIO-610
  964. [964] Item 1, Business — IBIO-610
  965. [965] Item 1, Business — IBIO-610
  966. [966] Item 1, Business — IBIO-610
  967. [967] Item 1, Business — IBIO-610
  968. [968] Item 1, Business — IBIO-610
  969. [969] Item 1, Business — IBIO-610
  970. [970] Item 1, Business — IBIO-610
  971. [971] Item 1, Business — IBIO-610
  972. [972] Item 1, Business — IBIO-610
  973. [973] Item 1, Business — IBIO-610
  974. [974] Item 1, Business — IBIO-610
  975. [975] Item 1, Business — IBIO-610
  976. [976] Item 1, Business — IBIO-610
  977. [977] Item 1, Business — IBIO-610
  978. [978] Item 1, Business — IBIO-610
  979. [979] Item 1, Business — IBIO-610
  980. [980] Item 1, Business — IBIO-610
  981. [981] Item 1, Business — IBIO-610
  982. [982] Item 1, Business — IBIO-610
  983. [983] Item 1, Business — IBIO-610
  984. [984] Item 1, Business — IBIO-610
  985. [985] Item 1, Business — IBIO-610
  986. [986] Item 1, Business — IBIO-610
  987. [987] Item 1, Business — IBIO-610
  988. [988] Item 1, Business — IBIO-610
  989. [989] Item 1, Business — IBIO-610
  990. [990] Item 1, Business — IBIO-610
  991. [991] Item 1, Business — IBIO-610
  992. [992] Item 1, Business — IBIO-610
  993. [993] Item 1, Business — IBIO-610
  994. [994] Item 1, Business — IBIO-610
  995. [995] Item 1, Business — IBIO-610
  996. [996] Item 1, Business — IBIO-610
  997. [997] Item 1, Business — IBIO-610
  998. [998] Item 1, Business — IBIO-610
  999. [999] Item 1, Business — IBIO-610
  1000. [1000] Item 1, Business — IBIO-610

Analysis on 8/28/2026